ARWR - Arrowhead says phase 3 trial of rare metabolic disease asset plozasiran meets goals
2024-06-03 12:24:00 ET
More on Arrowhead Pharmaceuticals
- Arrowhead Pharmaceuticals: Hoping Something Sticks
- Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point
- Arrowhead Pharmaceuticals secures $50M milestone from Royalty Pharma
- Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2024 Earnings Call Transcript
- Arrowhead Pharmaceuticals Q2 2024 Earnings Preview